Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder

Abstract The neural circuits of the infant brain are rapidly established near 6 months of age, but neurodevelopmental disorders can be diagnosed only at the age of 2–3 years using existing diagnostic methods. Early diagnosis is very important to alleviate life-long disability in patients through app...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	So-Hee Lim, Yun-Ju Sung, Narae Jo, Na-Yoon Lee, Kyoung-Shim Kim, Da Yong Lee, Nam-Soon Kim, Jeehun Lee, Ju-Young Byun, Yong-Beom Shin, Jae-Ran Lee
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c6d97dc35d924530bfecbe6899a38c80
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6d97dc35d924530bfecbe6899a38c80
record_format	dspace
spelling	oai:doaj.org-article:c6d97dc35d924530bfecbe6899a38c802021-11-28T12:19:23ZNanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder10.1038/s41598-021-02262-72045-2322https://doaj.org/article/c6d97dc35d924530bfecbe6899a38c802021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02262-7https://doaj.org/toc/2045-2322Abstract The neural circuits of the infant brain are rapidly established near 6 months of age, but neurodevelopmental disorders can be diagnosed only at the age of 2–3 years using existing diagnostic methods. Early diagnosis is very important to alleviate life-long disability in patients through appropriate early intervention, and it is imperative to develop new diagnostic methods for early detection of neurodevelopmental disorders. We examined the serum level of secretogranin II (SCG2) in pediatric patients to evaluate its potential role as a biomarker for neurodevelopmental disorders. A plasmonic immunosensor performing an enzyme-linked immunosorbent assay (ELISA) on a gold nanodot array was developed to detect SCG2 in small volumes of serum. This nanoplasmonic immunosensor combined with tyramide signal amplification was highly sensitive to detect SCG2 in only 5 μL serum samples. The analysis using the nanoplasmonic immunosensor revealed higher serum SCG2 levels in pediatric patients with developmental delay than in the control group. Overexpression or knockdown of SCG2 in hippocampal neurons significantly attenuated dendritic arborization and synaptic formation. These results suggest that dysregulated SCG2 expression impairs neural development. In conclusion, we developed a highly sensitive nanoplasmonic immunosensor to detect serum SCG2, a candidate biomarker for the early diagnosis of neurodevelopmental disorders.So-Hee LimYun-Ju SungNarae JoNa-Yoon LeeKyoung-Shim KimDa Yong LeeNam-Soon KimJeehun LeeJu-Young ByunYong-Beom ShinJae-Ran LeeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q So-Hee Lim Yun-Ju Sung Narae Jo Na-Yoon Lee Kyoung-Shim Kim Da Yong Lee Nam-Soon Kim Jeehun Lee Ju-Young Byun Yong-Beom Shin Jae-Ran Lee Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder
description	Abstract The neural circuits of the infant brain are rapidly established near 6 months of age, but neurodevelopmental disorders can be diagnosed only at the age of 2–3 years using existing diagnostic methods. Early diagnosis is very important to alleviate life-long disability in patients through appropriate early intervention, and it is imperative to develop new diagnostic methods for early detection of neurodevelopmental disorders. We examined the serum level of secretogranin II (SCG2) in pediatric patients to evaluate its potential role as a biomarker for neurodevelopmental disorders. A plasmonic immunosensor performing an enzyme-linked immunosorbent assay (ELISA) on a gold nanodot array was developed to detect SCG2 in small volumes of serum. This nanoplasmonic immunosensor combined with tyramide signal amplification was highly sensitive to detect SCG2 in only 5 μL serum samples. The analysis using the nanoplasmonic immunosensor revealed higher serum SCG2 levels in pediatric patients with developmental delay than in the control group. Overexpression or knockdown of SCG2 in hippocampal neurons significantly attenuated dendritic arborization and synaptic formation. These results suggest that dysregulated SCG2 expression impairs neural development. In conclusion, we developed a highly sensitive nanoplasmonic immunosensor to detect serum SCG2, a candidate biomarker for the early diagnosis of neurodevelopmental disorders.
format	article
author	So-Hee Lim Yun-Ju Sung Narae Jo Na-Yoon Lee Kyoung-Shim Kim Da Yong Lee Nam-Soon Kim Jeehun Lee Ju-Young Byun Yong-Beom Shin Jae-Ran Lee
author_facet	So-Hee Lim Yun-Ju Sung Narae Jo Na-Yoon Lee Kyoung-Shim Kim Da Yong Lee Nam-Soon Kim Jeehun Lee Ju-Young Byun Yong-Beom Shin Jae-Ran Lee
author_sort	So-Hee Lim
title	Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder
title_short	Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder
title_full	Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder
title_fullStr	Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder
title_full_unstemmed	Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder
title_sort	nanoplasmonic immunosensor for the detection of scg2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c6d97dc35d924530bfecbe6899a38c80
work_keys_str_mv	AT soheelim nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT yunjusung nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT naraejo nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT nayoonlee nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT kyoungshimkim nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT dayonglee nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT namsoonkim nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT jeehunlee nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT juyoungbyun nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT yongbeomshin nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder AT jaeranlee nanoplasmonicimmunosensorforthedetectionofscg2acandidateserumbiomarkerfortheearlydiagnosisofneurodevelopmentaldisorder
_version_	1718408101370003456

Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder

Ejemplares similares